Anticancer peptide, and pharmaceutical and health supplement compositions for cancer prevention and treatment containing it as an active ingredient

A 4-amino acid peptide that targets cancer cells by blocking the DNA binding of the transcription factor CP2c

This technology features an anticancer peptide with the Tyr-Pro-Gln-Arg sequence that binds to the transcription factor CP2c, modified peptides linked with terminal modifications, RGD-containing peptides, or biotin-conjugated Lys, as well as pharmaceutical and health supplement compositions for cancer prevention and treatment containing these as active ingredients.

Existing natural, protein-based, and chemically synthesized anticancer drugs often cause severe side effects by affecting healthy cells and are frequently ineffective depending on the cancer type or patient. CP2c is maintained at low levels in normal cells but is overexpressed in tumor cells, playing a key role in cancer development. As only a few substances, such as small-molecule compounds, have been reported to inhibit it, there was a need for more effective means to block CP2c activity.

This technology allows short peptides to stably cross cell membranes, bind specifically to CP2c, and inhibit its DNA-binding ability, thereby selectively disrupting CP2c-mediated cancer cell-specific transcriptional activity. Various variants can be designed through terminal acetylation, amidation, and the attachment of functional peptides. Applicable to targeted therapies for CP2c-overexpressing solid tumors like liver cancer, peptide-based anticancer adjuvants, and health supplements for cancer prevention, it provides a peptide drug platform that directly targets cancer cell transcription mechanisms while minimizing damage to healthy cells.

‍

‍

Key Features:

• Anticancer peptide of SEQ ID NO: 1, consisting of the Tyr-Pro-Gln-Arg sequence that binds to the transcription factor CP2c
• Peptide of SEQ ID NO: 1 with an acetyl group attached to the N-terminal Tyr and an amide group attached to the C-terminal Arg
• Peptide in which the C-terminal Arg is linked to the SEQ ID NO: 2 peptide (Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys) with a biotin-conjugated Lys attached to its terminus
• Pharmaceutical compositions for cancer prevention and treatment and health supplement compositions for cancer prevention and improvement containing the peptide as an active ingredient

‍

This invention was developed with support from the Ministry of Science, ICT and Future Planning for research into the mechanisms of tumor stem cell differentiation induced by chromatin remodeling factors.

‍